ES3055488T3 - Tegavivint for use in the treatment of pulmonary fibrosis - Google Patents
Tegavivint for use in the treatment of pulmonary fibrosisInfo
- Publication number
- ES3055488T3 ES3055488T3 ES18809912T ES18809912T ES3055488T3 ES 3055488 T3 ES3055488 T3 ES 3055488T3 ES 18809912 T ES18809912 T ES 18809912T ES 18809912 T ES18809912 T ES 18809912T ES 3055488 T3 ES3055488 T3 ES 3055488T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- tegavivint
- compound
- cells
- pulmonary fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514541P | 2017-06-02 | 2017-06-02 | |
| PCT/US2018/035646 WO2018223023A1 (en) | 2017-06-02 | 2018-06-01 | Methods for treatment of fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3055488T3 true ES3055488T3 (en) | 2026-02-12 |
Family
ID=64456126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18809912T Active ES3055488T3 (en) | 2017-06-02 | 2018-06-01 | Tegavivint for use in the treatment of pulmonary fibrosis |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11298346B2 (https=) |
| EP (2) | EP4656191A1 (https=) |
| JP (1) | JP7159302B2 (https=) |
| CA (1) | CA3065318A1 (https=) |
| ES (1) | ES3055488T3 (https=) |
| WO (1) | WO2018223023A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| JP7551507B2 (ja) * | 2018-06-01 | 2024-09-17 | イテリオン・セラピューティクス・インコーポレイテッド | テガビビントおよび関連化合物の製剤 |
| EP4081209A4 (en) | 2019-12-24 | 2024-04-24 | The Regents of the University of California | Compositions and methods for treating cancer and improving epithelial homeostasis |
| JP2023520867A (ja) * | 2020-04-08 | 2023-05-22 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | 損傷後の顔面拘縮に対処するための治療戦略 |
| US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
| US11571388B2 (en) * | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
| US11964054B2 (en) | 2020-11-24 | 2024-04-23 | Iterion Therapeutics, Inc. | Formulations of tegavivint |
| CN119215047A (zh) * | 2024-10-11 | 2024-12-31 | 浙江大学 | 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2152258T (pt) * | 2007-05-10 | 2016-08-18 | Avalon Pharmaceuticals | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona e acridina e suas utilizações |
| EA030302B1 (ru) * | 2008-11-21 | 2018-07-31 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
| US8957107B2 (en) | 2009-12-15 | 2015-02-17 | The Hospital For Sick Children | Method of treating scars and β-catenin-mediated disorders using Nefopam compounds |
| EP2773607B1 (en) | 2011-11-06 | 2017-03-29 | Beta Cat Pharmaceuticals LLC | Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia |
| US20130123281A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
| AU2014244506A1 (en) | 2013-03-14 | 2015-09-17 | Curegenix, Inc. | Compounds for treatment of fibrosis diseases |
| TW201718495A (zh) | 2015-07-28 | 2017-06-01 | 貝塔貓製藥股份有限公司 | 蒽-9, 10-二酮二肟化合物前驅藥及其用途 |
| KR102651136B1 (ko) * | 2016-04-12 | 2024-03-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 그 제조 방법 |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| JP7551507B2 (ja) * | 2018-06-01 | 2024-09-17 | イテリオン・セラピューティクス・インコーポレイテッド | テガビビントおよび関連化合物の製剤 |
| US11571388B2 (en) * | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
-
2018
- 2018-06-01 EP EP25199000.8A patent/EP4656191A1/en active Pending
- 2018-06-01 EP EP18809912.1A patent/EP3630101B1/en active Active
- 2018-06-01 US US15/995,917 patent/US11298346B2/en active Active
- 2018-06-01 CA CA3065318A patent/CA3065318A1/en active Pending
- 2018-06-01 WO PCT/US2018/035646 patent/WO2018223023A1/en not_active Ceased
- 2018-06-01 ES ES18809912T patent/ES3055488T3/es active Active
- 2018-06-01 JP JP2020516787A patent/JP7159302B2/ja active Active
-
2022
- 2022-03-29 US US17/707,486 patent/US20230012615A1/en active Pending
-
2025
- 2025-12-09 US US19/413,648 patent/US20260102382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630101B1 (en) | 2025-10-08 |
| US11298346B2 (en) | 2022-04-12 |
| WO2018223023A1 (en) | 2018-12-06 |
| US20180344713A1 (en) | 2018-12-06 |
| EP3630101A4 (en) | 2021-01-20 |
| US20260102382A1 (en) | 2026-04-16 |
| EP4656191A1 (en) | 2025-12-03 |
| JP7159302B2 (ja) | 2022-10-24 |
| JP2020522567A (ja) | 2020-07-30 |
| EP3630101A1 (en) | 2020-04-08 |
| US20230012615A1 (en) | 2023-01-19 |
| CA3065318A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3055488T3 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| AU2018256605C1 (en) | Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis | |
| US10905701B2 (en) | Compositions and methods for inhibiting arginase activity | |
| CN102985085B (zh) | 治疗双相型障碍的方法 | |
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| KR20050042154A (ko) | 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물 | |
| JP2007536241A (ja) | 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト | |
| AU2012255935A1 (en) | Compounds for use in treatment of mucositis | |
| WO2012158672A2 (en) | Compounds for use in treatment of mucositis | |
| CN106999540A (zh) | 组合疗法 | |
| BR112020000827A2 (pt) | métodos de tratamento de alterações de comportamento | |
| US20220193053A1 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| CN101321523A (zh) | Cb1拮抗剂在治疗精神分裂症的阴性症状中的用途 | |
| ES2983998T3 (es) | Compuesto de indol para tratar la cistitis intersticial | |
| EP3706744B1 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| JP2016029033A (ja) | 組合せ物 | |
| EP3833354B1 (en) | Tissue transglutaminase modulators for medicinal use | |
| EP4469092A1 (en) | Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy | |
| TW201806601A (zh) | σ受體配體在皰疹後遺疼痛中的用途 | |
| CN115697316A (zh) | 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途 | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo |